The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•25 March 2026•

1 min read

Quoin Pharmaceuticals Receives Positive FDA Feedback on QRX003 Regulatory Path

Key Facts

1The FDA indicated that a single Phase 3 study may be sufficient to support marketing approval for QRX003.

2The FDA expressed openness to an alternative Phase 3 study design that would likely not include a traditional placebo control.

3The company plans to initiate Phase 3 and complete recruitment in 2026, with a potential NDA filing in 2027.

Quoin Pharmaceuticals Ltd. (QNRX) announced a significant regulatory update following a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its QRX003 candidate. The FDA indicated that a single Phase 3 study may be sufficient to support the marketing approval of the drug, which targets Netherton Syndrome. Furthermore, the agency expressed openness to an alternative study design that would likely exclude a traditional placebo control, simplifying the clinical process. Quoin plans to initiate the Phase 3 trial and complete patient recruitment by 2026, targeting a potential New Drug Application (NDA) filing in 2027. This development is seen as a major milestone for the company, as it potentially reduces clinical trial costs and execution risks. Investors are reacting positively to the clarified and potentially shorter regulatory path for the company's lead asset in the rare disease space.

Create Free Account